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Summary  Tricuspid  valve  disease  is  mainly  represented  by  tricuspid  regurgitation  (TR),  which
is a  predictor  of  poor  outcome.  TR  is  usually  secondary,  caused  by  right  ventricle  pressure  or
volume overload,  the  leading  cause  being  left-sided  heart  valve  diseases.  Tricuspid  surgery  for
severe TR  is  recommended  during  left  valve  surgery,  and  consists  of  either  a  valve  replacement
or, most  often,  a  tricuspid  repair  with  or  without  prosthetic  annuloplasty.  When  TR  persists  orValvular  heart worsens after  left  valvular  surgery,  redo  isolated  tricuspid  surgery  is  associated  with  high  mortal-
diseases;
Transcatheter  valve
implantation
ity. In  addition,  a  sizeable  proportion  of  patients  present  with  tricuspid  surgery  deterioration
over time,  and  need  a  reintervention,  which  is  associated  with  high  morbi-mortality  rates.
In this  context,  and  given  the  recent  major  breakthrough  in  the  percutaneous  treatment  of
aortic and  mitral  valve  diseases,  the  tricuspid  valve  appears  an  appealing  challenge,  although  it
Abbreviations: BP, bioprosthesis; CT, computed tomography; IVC, inferior vena cava; NYHA, New York Heart Association; RA, ring annulo-
plasty; RVP, rapid ventricular pacing; TEE, transoesophageal echocardiography; THV, transcatheter heart valve; TR, tricuspid regurgitation.
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raises  speciﬁc  issues.  The  ﬁrst  applications  of  transcatheter  techniques  for  tricuspid  valve  dis-
ease were  valve-in-valve  and  valve-in-ring  implantation  for  degenerated  bioprosthesis  or  ring
annuloplasty.  Some  concerns  remain  regarding  prosthesis  sizing,  rapid  ventricular  pacing  and
the best  approach,  but  these  procedures  appear  to  be  safe  and  effective.  More  recently,  bicus-
pidization  using  a  transcatheter  approach  for  the  treatment  of  native  tricuspid  valve  has  been
published,  in  two  patients.  Finally,  other  devices  are  in  preclinical  development.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  La  pathologie  tricuspide  est  le  plus  souvent  une  insufﬁsance  tricuspide  (IT),  qui  est
un facteur  de  mauvais  pronostic.  L’IT  est  en  général  secondaire  à  une  surcharge  de  pression  ou
de volume  du  ventricule  droit,  la  première  cause  en  étant  une  valvulopathie  gauche.  Durant
une chirurgie  valvulaire  gauche,  la  correction  d’une  IT  sévère  est  recommandée  et  consiste
en un  remplacement  valvulaire  tricuspide  ou  en  une  plastie  tricuspide  avec  ou  sans  anneau
prothétique.  Si  l’IT  persiste  après  une  opération  du  cœur  gauche,  une  chirurgie  redux  dédiée
est grevée  d’une  lourde  mortalité.  Par  ailleurs,  une  proportion  non  négligeable  de  patients
présentent une  détérioration  de  leur  chirurgie  tricuspide  au  cours  du  temps  et  requièrent  une
réintervention,  associée  à  une  morbi-mortalité  élevée.  Au  vu  des  récentes  avancées  des  tech-
niques percutanées  concernant  les  valves  aortiques  et  mitrales,  la  valve  tricuspide  apparaît
comme un  challenge  déﬁ  majeur,  malgré  des  obstacles  propres.  Les  premières  applications  ont
été les  techniques  percutanées  de  « valve-in-valve  » et  de  « valve-in-ring  » pour  les  dégénéres-
cences de  bioprothèse  et  d’anneau  tricuspides.  Même  si  des  questions  persistent  concernant
l’évaluation  optimale  de  la  taille  de  prothèse  à  implanter,  la  stimulation  ventriculaire  rapide  ou
l’approche  la  plus  appropriée,  ces  procédures  apparaissent  sûres  et  efﬁcaces.  Plus  récemment,
la bicuspidisation  percutanée  a  été  publiée  chez  2  patients  pour  le  traitement  d’une  IT  sur
valve native.  Enﬁn,  d’autres  procédés  sont  en  développement  au  stade  préclinique.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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tackground
ysfunction  of  a  native  or  previously  operated  tricus-
id  valve  encompasses  a  variety  of  situations,  which  are
requently  sources  of  difﬁculty  in  patient  management.  Tri-
uspid  disease  is  most  often  tricuspid  regurgitation  (TR),
hich  is  mainly  secondary  to  left-sided  heart  valve  disease
1].  Tricuspid  valve  disease  has  long  been  ignored,  with  the
elief  that  TR  would  improve  after  surgical  correction  of
eft  valve  disease.  A  large  body  of  evidence  now  supports  the
egative  effect  of  signiﬁcant  TR,  and  this  recognition  has  led
o  more  frequent  indications  for  combined  tricuspid  surgery,
ith  the  inherent  risk  of  subsequent  dysfunction  of  tricuspid
epair  or  replacement  [2,3].  Whatever  the  clinical  context,
edo  tricuspid  valve  surgery  is  often  associated  with  high
orbi-mortality  rates.  Following  the  recent  development  of
ranscatheter  therapies  for  aortic  and  mitral  valve  diseases,
he  possibility  of  lower-risk  tricuspid  valve  intervention  is
herefore  particularly  attractive.
This  review  presents  current  status  and  perspectives
egarding  transcatheter  therapies  for  tricuspid  valve  dis-
ase,  both  for  bioprosthesis  or  ring  annuloplasty  failure  and
or  native  valves.
c
w
sationale for percutaneous treatment of
ricuspid valve disease
ative  tricuspid  valve  disease  can  be  either  stenotic  or
egurgitant.  The  extremely  rare  stenotic  lesions,  caused
ainly  by  rheumatic  fever  or  carcinoid  syndrome,  will  not  be
ddressed  in  this  paper.  The  most  common  disease  of  the  tri-
uspid  valve  is  regurgitation,  which  is  more  often  secondary
ather  than  caused  by  a primary  valve  lesion,  particularly
n  Western  countries  [1].  Secondary  TR  is  caused  by  annular
ilatation  and  increased  tricuspid  leaﬂet  tethering  in  rela-
ion  to  right  ventricular  pressure  and/or  volume  overload
4].  Pressure  overload  is  most  often  caused  by  pulmonary
ypertension  resulting  from  left-sided  heart  disease  or,  less
requently,  pulmonary  disease,  while  right  ventricular  vol-
me  overload  is  observed  in  left-to-right  shunts  or  intrinsic
isease  of  the  right  ventricle.
TR  has  a  strong  negative  effect  on  outcomes  [5—8].  In
 study  of  more  than  5200  patients  followed  for  longer
han  5  years  [5],  both  moderate  and  severe  TR  were  asso-
iated  with  increased  mortality.  Moderate  TR  may  indeed
orsen  during  long-term  follow-up  after  surgery  for  left-
ided  valvular  disease,  and  is  also  associated  with  decreased
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Figure 1. Measurement of the inner diameter of an annuloplasty ring (A and B) and bioprosthesis (C) by: (A) ﬂuoroscopy; (B) three-
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survival  [9].  Similarly,  residual  signiﬁcant  TR  after  mitral
surgery  was  responsible  for  a  four-fold  increase  in  late  mor-
tality  in  a  recent  study  [10].  However,  management  of  these
patients  with  isolated  severe  functional  TR  after  previous
left-sided  valvular  surgery  is  difﬁcult  because  of  the  inher-
ent  risk  of  redo  interventions.  Indeed,  operative  mortality
was  15%  in  a  series  of  82  patients  undergoing  tricuspid
surgery,  of  whom  73%  had  had  previous  left-sided  heart
surgery  [11].
Tricuspid  annuloplasty  is  effective  in  reducing  the  sever-
ity  of  functional  TR,  improves  right  ventricle  geometry  and
function,  and  has  a  favourable  effect  on  mortality  [12—18].
Tricuspid  valve  replacement  is  usually  limited  to  anatomy
unsuitable  for  repair.  Guidelines  recommend  the  consid-
eration  of  wide  indications  for  combined  tricuspid  surgery
in  patients  undergoing  left-sided  heart  valve  surgery  [2,3].
However,  a  number  of  patients  now  present  with  late  pros-
thetic  dysfunction  after  tricuspid  repair  or  replacement.
After  previous  tricuspid  valve  surgery,  recurrence  of  moder-
ate  or  severe  TR  may  be  as  high  as  60%  at  5 years  [19], and
reoperation  is  necessary  in  approximately  20%  of  patients
within  10  years  after  tricuspid  valve  surgery  [20].  While  redo
surgery  is  the  treatment  of  choice  for  a  degenerated  bio-
prosthesis  (BP)  or  deterioration  of  ring  annuloplasty  (RA),  it
may  be  associated  with  a  very  high  mortality  rate  [21—24],
reaching  35%  at  30  days  [25],  particularly  in  patients  with
co-morbidities  [16,20].
Uncertainties  concerning  the  risk—beneﬁt  ratio  of
surgery  in  severe  functional  TR  or  dysfunction  after  tricus-
pid  surgery  therefore  justify  the  search  for  less  invasive
approaches.
Since  its  ﬁrst  steps  [26],  the  efﬁcacy  of  transaortic  valve
implantation  has  led  over  time  to  transition  to  valve-in-valve
implantation  for  a  failing  aortic  BP  and,  more  recently,  for
mitral  BP  and  RA  deterioration,  with  favourable  immedi-
ate  and  mid-term  outcomes  [27,28].  Tricuspid  valve-in-valve
and  valve-in-ring  implantation  may  therefore  present  a new
therapeutic  option.  More  recently,  transcather  repair  tech-
niques  have  been  described  to  correct  functional  TR  in
native  valves.
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ranscatheter  heart  valve  (THV)  implantation  has  recently
een  reported  for  the  treatment  of  a  degenerated  tricuspid
P  or  failure  of  RA  [29—49].
Whereas  the  technique  for  valve-in-valve  shares  features
ith  procedures  for  aortic  or  mitral  valves,  the  valve-in-
ing  implantation  presents  speciﬁc  challenges  because  of  the
ricuspid  position  [30].
ricuspid bioprosthesis failure and
alve-in-valve implantation
rosthesis measurements
ne  of  the  main  difﬁculties  associated  with  the  procedure
s  the  proper  evaluation  of  prosthesis  size.  For  tricuspid
P,  as  for  aortic  or  mitral  valve-in-valve,  the  prosthesis
ize  may  be  derived  from  an  integrated  approach,  tak-
ng  into  account  the  manufacturer’s  inner  diameters  and
he  mean  diameter  determined  by  computed  tomography
CT),  three-dimensional  transoesophageal  echocardiogra-
hy  (TEE)  and  ﬂuoroscopy.  Whenever  possible,  the  three
vailable  techniques  should  be  used  systematically  in  the
bsence  of  recommendations  for  the  assessment  of  pros-
hesis  size  (Fig.  1).  However,  given  the  round  shape  of  the
rostheses,  and  based  on  the  experience  of  the  centre,
 reliable  CT  scan  measurement  may  be  sufﬁcient.  Based
n  our  experience,  ﬂuoroscopy  usually  provides  the  largest
imensions  while  TEE  gives  the  smallest  ones  [30].
ranscatheter heart valve implantation
rocedures
he  routes  reported  so  far  for  tricuspid  implantations
ave  been  mainly  transatrial  or  transjugular  accesses
29,32—34,36,37,40,42,43,46,48,49].  However,  the  trans-
emoral  route  has  also  provided  good  results,  conﬁrming
he  technical  feasibility  of  this  approach  [30,31]. The
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Figure 2. Transcatheter heart valve (THV) implantation in a degenerated bioprosthesis in the tricuspid position. A. After the tricuspid
bioprosthesis valve has been crossed with a Judkins right diagnostic catheter or a balloon ﬂotation catheter, a stiff wire is placed at the apex
of the right ventricle. B. The THV is placed within the tricuspid valve and inﬂated using rapid ventricular pacing. Final result after tricuspid
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hree-dimensional reconstruction (F, H, I).
voidance  of  a  thoracotomy,  with  its  potential
omplications,  is  deemed  desirable  given  the  high-risk
roﬁle  of  the  candidates  regarding  such  techniques.  In
he  published  transfemoral  approach  series  of  the  Bichat
entre,  no  technical  difﬁculty  was  observed  [27].
In  our  institution,  transfemoral  procedures  are  per-
ormed  under  general  anaesthesia  and  TEE  guidance.  After
rossing  the  tricuspid  valve,  a  J-shaped  guidewire  is  placed
t  the  apex  of  the  right  ventricle  (Fig.  2);  then,  an  Edwards
APIENTM XT  valve  (and  more  recently  the  SAPIENTM 3  valve)
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igure 3. Different options for rapid ventricular pacing when implan
ead in the coronary sinus; (B) lead in the left ventricle; and (C) epicardd using computed tomography (E, G) and computed tomography
Edwards  Lifesciences,  Irvine,  CA,  USA),  mounted  upside
own  on  the  catheter,  is  deployed  by  slow  balloon  inﬂa-
ion  under  rapid  ventricular  pacing  (RVP)  (140—180  beats  per
inute).  RVP  is  performed  using  either  a  temporary  lead  in
he  left  ventricle  or  in  the  coronary  sinus,  or  using  a  perma-
ent  pacemaker  implanted  before  the  procedure  (Fig.  3).
redilatation  of  the  BP  should  be  avoided  as  often  as  pos-
ible  to  prevent  the  risk  of  cusp  rupture  or  embolization,
lthough  their  consequences  are  less  severe  than  for  left-
ided  valves.  The  results  are  assessed  in  the  catheterization
ting a valve-in-valve or valve-in-ring in the tricuspid position: (A)
ial pacemaker.
Percutaneous  treatment  of  tricuspid  valve  diseases  
Figure 4. Final result after tricuspid valve-in-ring implantation in
the catheterization laboratory (A, B), with post-implantation com-
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tional  lead  in  the  coronary  sinus  may  also  be  discussed  toputed tomography scan control (C, D) and computed tomography
three-dimensional reconstruction (E, F).
laboratory  by  haemodynamics,  TEE  and  ﬂuoroscopy,  then  a
CT  scan  with  three-dimensional  reconstruction  is  performed
before  discharge  (Fig.  4).
Choice of valve: Melody® or Edwards
SAPIENTM?
THV  implantation  in  a  degenerated  tricuspid  BP  has
been  reported  using  two  different  valves:  the  Melody®
valve  (Medtronic,  Minneapolis,  MN,  USA)  and  the  Edwards
SAPIENTM valve.
A  series  of  15  Melody® valve  implantations  in  biopros-
thetic  tricuspid  valves  in  patients  with  a  median  age  of
31.5  years,  most  of  whom  had  congenital  heart  disease,
reported  good  results  [45].  The  valve  was  successfully  placed
in  all  patients  and  the  median  follow-up  was  4  months.
Complications  were  one  death  in  a  patient  with  preproce-
dural  multiorgan  failure,  one  third-degree  atrioventricular
block  requiring  pacemaker  implantation  and  one  case  of
endocarditis  2  months  after  implantation.  However,  recent
concerns  have  been  raised  regarding  the  increased  risk  of
infective  endocarditis  in  the  Melody® valve,  although  mainly
in  the  pulmonary  position  [50,51].
p
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A  number  of  cases  and  series  have  also  been
ublished  using  the  Edwards  SAPIENTM valve
29,31—34,36,39—44,46,47,49].  A recent  review  of  the
iterature  [52]  reported  eight  case  reports  using  the
dwards  SAPIENTM valve  in  patients  aged  8—74  years.  All
rocedures  had  good  results  without  complications,  and  the
alve  performance  after  implantation  was  good,  similar  to
he  results  of  the  series  with  Melody® valve  implantations
45], but  the  mean  reported  follow-up  was  only  3  months.
A  recent  series  of  16  patients  implanted  between  2008
nd  2014  has  been  published  with  both  the  Melody® valve
n  =  7)  and  the  Edwards  SAPIENTM valves  (SAPIENTM XT  26,
 =  4;  SAPIENTM XT  29,  n  =  6)  [53]. The  procedural  success
eached  100%  in  this  series  of  young  patients  (median  age
1  years),  most  of  whom  had  congenital  heart  disease  (14
atients)  and  only  two  of  whom  had  an  initially  acquired
ricuspid  dysfunction.
In  Bichat  hospital,  we  implanted  four  patients  with
 BP  failure,  all  of  whom  had  acquired  tricuspid  dys-
unction  (three  of  rheumatic  origin  and  one  endocarditis)
unpublished  results).  This  was  a  very  different  population
ompared  to  patients  with  congenital  heart  disease,  with
 mean  age  of  56  years,  and  all  patients  were  implanted
ith  an  Edwards  SAPIENTM XT  valve  (26  mm,  n  =  2;  29  mm,
 =  2).  Of  these  four  patients,  two  were  already  tridux,  one
as  already  redux  and  the  last  patient  had  a  history  of  drug
se  and  infective  endocarditis.  For  the  degenerated  BP,  two
ad  stenotic  impairment,  and  two  had  both  regurgitant  and
tenotic  BP  failure.  The  procedural  success  was  100%  with
o  conversion  to  surgery.  During  in-hospital  follow-up,  two
omplications  occurred:  one  major  gastrointestinal  bleeding
elated  to  oesophageal  ulceration  and  one  severe  vascular
omplication  needing  surgical  management  as  a  result  of
enous  subcutaneous  bleeding  at  the  puncture  site.  No  other
omplication  occurred  at  30-day  follow-up.
Both  the  Melody® valve  and  the  Edwards  SAPIENTM XT
alve  seem  to  give  good  results  for  THV  implantation  in  the
ricuspid  position.  However,  given  the  small  sizes  available
or  the  Melody® valve  (maximal  diameter  of  22  mm),  it  may
e  less  adequate  for  adult  patients  with  acquired  valve  dis-
ase.  In  our  series,  for  example,  the  sizes  of  the  failed  BPs
ere  between  25  and  31  mm,  which  is  not  compatible  with
elody® valve  implantation.  Moreover,  larger  studies  with
 longer  follow-up  need  to  be  conducted  to  assess  whether
he  risk  of  infective  endocarditis  is  really  more  important
ith  the  Melody® valve.
apid ventricular pacing: speciﬁcities for
ricuspid transcatheter heart valve
mplantation
or  THV  implantation  in  the  tricuspid  position,  RVP  should
ot  be  performed  via  a  temporary  right  ventricular  pacing
ead,  should  the  lead  be  jailed  or  damaged  during  the  proce-
ure.  Several  other  strategies  may  be  proposed  [31,34,49].
For  patients  with  a  previous  permanent  pacemaker,  RVP
ay  be  performed  using  the  latter.  Implantation  of  an  addi-revent  any  adverse  event.
When  the  patients  do  not  have  a  pacemaker,  the  different
ptions  for  RVP  are  either  a temporary  lead  in  the  coronary
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inus  or  in  the  left  ventricle,  or  direct  pacing  using  the  wire
t  the  apex  of  the  right  ventricle  and  crocodile  forceps.
In  some  particular  cases,  when  the  risk  of  pacemaker
mplantation  is  very  high,  a  permanent  epicardial  pace-
aker  may  be  proposed  before  the  procedure.  These  options
re  feasible  without  major  difﬁculties  and  the  choice  must
e  individualized  to  patients’  characteristics  (Fig.  3).
nnuloplasty rings failure: speciﬁcities of
alve-in-ring implantation
ll  the  challenges  previously  described  for  valve-in-valve
mplantation  also  apply  to  valve-in-ring  procedures.  Addi-
ionally,  tricupid  annuloplasty  rings  present  some  speciﬁc
ifﬁculties.
nnulus measurements
rosthesis  sizing  is  particularly  difﬁcult  for  prosthetic  tri-
uspid  rings,  which  are  non-circular,  as  illustrated  in
igs.  1  and  4,  and  surrounded  by  valvular  tissue  that  can-
ot  be  detected  by  CT  scan  or  ﬂuoroscopy.  In  this  setting,  it
s  therefore  mandatory  to  systematically  use  the  three  avail-
ble  techniques  (CT  scan,  TEE  and  ﬂuoroscopy)  to  determine
he  most  appropriate  size  of  prosthesis  by  using  an  inte-
rated  approach.  The  aim  is  to  implant  the  valve  with  the
iameter  that  is  closest  to  the  mean  inner  diameter  of  the
ing,  to  avoid  over-  or  under-valve  expansion.
Moreover,  careful  balloon  sizing  at  the  beginning  of  the
rocedure  may  be  used  to  help  determine  the  annulus
imension  more  precisely  [54].
alve-in-ring implantations: mind the gap!
nly  three  case  reports  have  been  published  so  far  with
he  Edwards  SAPIENTM valve,  using  the  transatrial  [42]  and
ransfemoral  [55,56]  approaches.
A  recent  series  of  three  valve-in-ring  implantations  with
n  Edwards  SAPIENTM XT  valve  through  the  transfemoral
pproach  has  been  published  [30].  The  sizes  of  the  failed
As  were  between  30  and  32  mm,  allowing  for  implantation
f  three  26  mm  Edwards  SAPIENTM XT  stents.  The  authors
eported  one  patient  with  a  moderate-to-severe  residual
egurgitation  immediately  after  the  procedure,  in  a  rigid  and
ncomplete  ring  (Carpentier-Edwards  Classic  Ring;  Edwards
ifesciences,  Irvine,  CA,  USA).  The  regurgitation  was  caused
y  a  paravalvular  leak  at  the  level  of  the  open  portion  of  the
ing.  Another  patient  had  mild  post-procedural  paravalvular
egurgitation,  in  the  same  type  of  rigid  and  open  ring.
In  a  recent  case  report,  a  22  mm  Melody® valve  was
mplanted  in  a  26  mm  failed  RA  in  a  21-year-old  young
omen  [54].  A  severe  paravalvular  leak  occurred  in  the
egion  where  the  tricuspid  ring  was  incomplete.  This  case
lso  concerned  a  Carpentier-Edwards  Classic  tricuspid  annu-
oplasty  ring.  The  authors  report  the  successful  closure  of
he  paravalvular  leak  using  an  AMPLATZERTM Vascular  Plug
I  (St.  Jude  Medical,  St.  Paul,  MN,  USA),  with  only  a mild
esidual  leak  as  the  ﬁnal  result  [54].
The  presence  of  a  prosthetic  ring  has  the  advantage  of
roviding  the  ﬂuoroscopic  landmarks  and  necessary  anchor-
ng  for  a  percutaneous  valve,  but  also  has  the  drawback
f  creating  a  non-circular  landing  zone,  with  the  inability
o  completely  seal  the  open  segment  with  the  THV,  and
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nducing  underexpansion  of  the  transcatheter  valve  in  the
mall  diameter  of  the  ring.  These  ﬁndings  are  more  likely  to
ppear  with  the  Carpentier-Edwards  Classic  tricuspid  rings,
hich  are  rigid,  making  it  difﬁcult  to  circularize  this  type  of
ing  (Fig.  4).
Residual  TR  is,  however,  probably  less  clinically  relevant
han  in  the  mitral  or  aortic  position.  Indeed,  we  reported
 sustained  improvement  in  the  functional  status  of  the
atient  with  severe  paravalvular  regurgitation,  who  was  in
ew  York  Heart  Association  (NYHA)  class  II at  1-year  follow-
p  [30].
THV  implantation  should,  however,  be  considered  with
aution  in  these  particular  rigid  and  open  rings.  In  this
etting,  semirigid  or  ﬂexible  rings  are  more  favourable  as
hey  are  easier  to  circularize  during  prosthesis  deployment,
hich  limits  paravalvular  regurgitations.  However,  they  are
sed  less  often  in  the  tricuspid  position.
These  emerging  techniques  of  valve-in-valve  and  valve-
n-ring  interventions  are  currently  limited  to  extremely
igh-risk  patients;  until  now,  150  patients  have  been  treated
round  the  world.  These  new  percutaneous  treatments  have
een  proposed  for  two  very  different  populations:  young
atients  with  congenital  heart  diseases  who  have  already
een  operated  on  several  times,  or  older  patients  with  co-
orbidities  and  acquired  valve  disease  who  are  exposed  to
he  risk  of  a  redo  surgery  at  least.  In  all  cases,  patients  either
ad  a  contraindication  to  surgery  or  were  considered  at  very
igh-risk  after  evaluation  by  the  heart  team.
Given  the  limited  experience  with  THV  implantation  in
he  tricuspid  position,  the  patients  who  beneﬁt  from  these
echniques  should  have  a  close  follow-up,  including  at  least
n  annual  visit  with  TEE  and  CT  scan  evaluation  in  the  centre
here  they  were  implanted.  It  is  mandatory  to  ensure  that
he  implanted  prosthesis  remains  functional  over  a  number
f  years,  without  any  deinsertion,  deterioration  or  throm-
osis,  before  considering  larger  indications  in  the  future.
ative tricuspid valve
alve-in-native valve implantation
esides  tricuspid  valve-in-valve  and  valve-in-ring  in  failed
P  or  RA,  Kefer  et  al.  reported  the  ﬁrst  case  of  THV  implan-
ation  in  a  native  tricuspid  valve  [57].  The  patient  was  a
7-year-old  woman  with  congenital  heart  disease  who  was
lready  tridux.  She  had  had,  in  addition  to  mitral  valve
eplacement  and  aortic  valve  replacement,  three  tricus-
id  valve  repair  interventions,  but  without  any  RA.  Her
ative  tricuspid  valve  was  both  stenotic  and  regurgitant.
here  was  no  rigid  target  zone  to  anchor  the  percutaneous
alve  and  no  ﬂuoroscopic  marker  to  help  THV  implantation.
herefore,  prestenting  was  performed  with  two  covered
4  mm  CP  StentsTM (NuMED,  Hopkinton,  NY,  USA)  to  create  a
igid  landing  zone.  An  Edwards  SAPIENTM valve  (26  mm)  was
mplanted  through  the  transfemoral  approach,  under  gen-
ral  anaesthesia,  with  ﬂuoroscopic  and  three-dimensional
EE  guidance.  Of  note,  the  procedure  was  performed  under
xtracorporeal  membrane  oxygenation  assistance  in  antici-
ation  of  haemodynamic  instability.  The  patient  needed  the
mplantation  of  a  second  26  mm  Edwards  SAPIENTM valve
ecause  the  position  of  the  ﬁrst  valve  was  too  low,  with
Percutaneous  treatment  of  tricuspid  valve  diseases  61
Figure 5. Kay Repair Technique (A and A’) and corresponding percutaneous approach using the Mitralign systemTM (Mitralign Inc., Tewks-
bury, MA, USA) (B and B’). A. Tricuspid valve bicuspidization is accomplished by plicating the annulus along the posterior leaﬂet (A’); the
sutures are tied, obliterating the posterior leaﬂet, creating a bicuspid valve. B. Image of the native tricuspid annulus before repair and (B’)
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important  regurgitation.  Finally,  the  result  was  good,  with
no  stenosis  and  only  a  trivial  central  leak.  At  5-month  follow-
up,  the  authors  reported  persistence  of  good  clinical  and
haemodynamic  results.
This  ﬁrst-in-man  implantation  is  encouraging,  but  larger
studies  are  needed  to  conﬁrm  the  feasibility,  safety  and
durability  of  this  therapy.
Caval valve implantation against severe
tricuspid regurgitation
A  technique  involving  heterotopic  placement  of  transcathe-
ter  aotic  valves  in  the  inferior  vena  cava  (IVC)  in  patients
with  refractory  ascites  and  lower  extremity  oedema  has
been  described  [58,59].  The  aim  was  to  reduce  venous
hypertension  in  the  hepatorenal  system  and  to  protect  from
the  systolic  backﬂow  encountered  in  severe  TR,  in  end-
stage  patients.  Short-term  results  showed  reductions  in
ascites,  hepatic  congestion  and  peripheral  oedema,  which
are  encouraging,  although  long-term  follow-up  of  this  pal-
liative  treatment  is  needed.  Currently,  this  therapy  is  being
evaluated  in  ‘The  Treatment  of  Severe  Secondary  TRIcus-
pid  Regurgitation  in  Patients  With  Advance  Heart  Failure
With  CAval  Vein  Implantation  of  the  Edwards  SAPIENTM
XT  VALve’  (TRICAVAL)  study  (ClinicalTrials.gov  identiﬁer:
NCT02387697).
Bicuspidization techniques: concept and ﬁrst
results
The  Mitralign  systemTM (Mitralign  Inc.,  Tewksbury,  MA,  USA)
was  initially  used  for  functional  mitral  regurgitation,  and  has
p
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aecently  been  adapted  for  functional  TR.  This  system  mimics
he  surgical  Kay  Repair  Technique  leading  to  bicuspidization
f  the  tricuspid  valve  (Fig.  5) [60],  by  placing  pledget  sutures
hrough  a  transjugular  venous  approach.  The  ﬁnal  result  is
 suture  supported  on  both  the  ventricular  and  atrial  sides
f  the  annulus,  with  folded  pledgets.
A  successful  procedure  was  reported  in  an  89-year-old
oman  with  recurrent  heart  decompensation  caused  by  iso-
ated  TR  [61].  The  patient’s  logistic  EuroSCORE  (European
ystem  for  Cardiac  Operative  Risk  Evaluation)  was  28%,
nd  surgical  intervention  was  deemed  too  high-risk.  The
rocedure  was  performed  under  general  anaesthesia  with
uoroscopy  and  two-  and  three-dimensional  TEE  guidance.
here  was  a  signiﬁcant  reduction  in  annular  area  by  57%
from  14.1  cm2 to  6.05  cm2)  and  in  effective  regurgitant  ori-
ce  area  by  53%  (from  1.35  to  0.65  cm2)  as  measured  using
hree-dimensional  TEE.  After  discharge,  the  patient  needed
ontinuation  of  her  usual  aggressive  medical  therapy,  but
elt  better,  with  less  oedema  and  improvement  in  renal  func-
ion.
Another  device,  the  TriCinch  SystemTM (4TECH  Cardio
td,  Galway,  Ireland),  also  leads  to  bicuspidization  of  the
ricuspid  valve  (Fig.  6)  [62]. The  percutaneous  device  is
peciﬁcally  dedicated  to  tricuspid  valve  remodelling,  by
eans  of  the  ﬁxation  of  a  stainless  steel  corkscrew  close
o  the  anteroposterior  commissure  of  the  tricuspid  valve.
he  corkscrew  is  connected  through  a  Dacron  band  to  a
elf-expanding  nitinol  stent  implanted  in  the  IVC  (Fig.  6).  By
ulling  the  system  towards  the  IVC,  the  anchoring  corkscrew
educes  the  anteroposterior  annulus,  and  the  tension  is
aintained  by  positioning  the  stent  in  the  IVC.  The  stent  is
vailable  in  different  sizes  (27—43  mm  in  diameter,  66  mm
62  C.  Bouleti  et  al.
Figure 6. The TriCinch SystemTM (4TECH Cardio Ltd, Galway Ireland). A. The anchor is attached on the anteroposterior commissure. B.
Tension is applied via the Dacron band in order to bicuspidize the tricuspid valve. C. Tension is maintained via a stent implanted in the
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Figure 7. Dimensions of the tricuspid annulus (A) before and (B)
after the bicuspidization technique, using the TriCinch SystemTM
(4TECH Cardio Ltd, Galway Ireland). The stent implanted in thenferior vena cava.
eproduced with permission from JACC Cardiovasc Interv [62].
n  length)  to  guarantee  oversizing  in  the  hepatic  region  of
he  IVC.
We  recently  published  the  ﬁrst-in-man  implantation  in
 72-year-old  woman,  NYHA  class  III,  as  a  result  of  severe
R  (grade  4),  a  9  mm  lack  of  coaptation  and  a  septolat-
ral  dimension  of  46  mm,  according  to  TEE  [63].  She  had
ad  a  previous  aortic  valve  replacement  with  a  BP.  The
rocedure  was  performed  under  general  anaesthesia,  with
uoroscopy,  two-  and  three-dimensional  TEE  and  intracar-
iac  echocardiographic  imaging  guidance.  The  procedure
sed  a  transfemoral  approach.  The  tip  of  the  delivery  system
as  successfully  steered  on  the  tricuspid  annulus,  and  ten-
ion  was  applied  and  maintained  by  implantation  of  a  43  mm
elf-expanding  nitinol  stent  in  the  IVC.  TR  was  reduced  from
rade  4  to  3,  and  the  septolateral  dimension  was  reduced
rom  46  mm  to  38  mm  [63].
The  results  of  three  successful  implantations  performed
n  Milan  and  Paris  in  2014  were  presented  at  the  last  EuroPCR
eeting  in  Paris  (May  2015)  [64].  The  ﬁnal  result  in  one  of  the
atients,  with  the  stent  implanted  in  the  IVC  and  a  reduc-
ion  in  tricuspid  annular  dimension  from  41  mm  to  34  mm,  is
llustrated  in  Fig.  7.  Follow-up  at  6  months  for  two  patients
nd  3  months  for  the  third  showed  improvement  of  at  least
ne  class  in  terms  of  functional  NYHA  evaluation,  and  a
ubstantial  improvement  in  the  6-minute  walk  test  in  the
hree  patients.  The  reduction  in  septolateral  dimension  was
aintained  and  the  device  was  stable  in  all  three  patients.
here  was  neither  migration  nor  stent  thrombosis.  The  PRE-
ENT  Study  (Percutaneous  Treatment  of  the  Tricuspid  valve
egurgitation  with  the  Tricinch  SystemTM;  ClinicalTrials.gov
dentiﬁer  NCT02098200)  is  still  ongoing  and  is  aiming  to
nroll  24  patients  for  CE  marking.
Transcatheter  tricuspid  valve  repair  for  severe  symp-
omatic  functional  TR  is  still  in  the  initial  stages  of
evelopment.  Regarding  efﬁcacy,  these  new  procedures  only
esulted  in  a  slight  reduction  in  TR,  which  may  be  sufﬁcient
inferior vena cava is visible on (C) the ﬁnal computed tomography
scan and (D) the three-dimensional reconstruction.
Percutaneous  treatment  of  tricuspid  valve  diseases  
Figure 8. Computed tomography scan tricuspid valve (TV) analy-
sis with the expected ideal target for the anchoring system of the
The TriCinch SystemTM (4TECH Cardio Ltd, Galway Ireland). APC:
anteroposterior commissure; ASC: anteroseptal commissure; MV:
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wmitral valve; PSC: posteriosuperior commissure; RCA: right coronary
artery.
for  symptomatic  improvement  in  these  patients.  There  are
still  many  unsolved  technical  issues.  Long-term  follow-up  is
required  to  assess  the  durability  of  the  device  and  its  long-
term  efﬁcacy.  More  patients  are  needed  to  test  both  the
safety  and  the  reproducibility  of  the  procedure  before  wider
use.
Regarding  the  TriCinch  SystemTM,  the  accurate  location  of
the  anchor  on  the  tricuspid  annulus  is  the  most  difﬁcult  step
to  achieve  under  echocardiographic  guidance  (even  using
both  TEE  and  intracardiac  imaging)  in  order  to  avoid  screw-
ing  in  the  free  wall  of  the  right  atrium  (with  the  risk  of
haemopericardium)  or  in  the  right  coronary  artery  that  sur-
rounds  the  tricuspid  annulus.  CT  scan  analysis  before  the
procedure  is  crucial  to  determine  the  optimal  target  for  the
anchor  implantation,  far  from  the  right  coronary  artery  and
the  aortic  root  (Fig.  8).
The future has begun
As  for  the  mitral  valve,  transcatheter  tricuspid  intervention
is  the  natural  evolution  of  modern  tricuspid  valve  surgery.
Currently  based  on  bicuspidization,  new  technologies  need
to  be  developed  to  expand  the  possibilities  of  transcatheter
intervention,  such  as  edge-to-edge  repairs  or  annuloplasty
(direct  or  indirect),  speciﬁcally  dedicated  to  the  anatomy
of  the  tricuspid  valve.
For  example,  the  use  of  the  MitraClip® System  (Abbott
Vascular,  Abbott  Park,  IL,  USA)  in  the  tricuspid  valve  was
ﬁrst  reported  in  one  patient  with  corrected  transposition
of  the  great  arteries,  through  a  transjugular  access  [65]. In
this  case,  the  patient  had  an  anatomically  left-sided  tricus-
pid  mitral  valve.  This  technique  is  currently  being  explored
to  attempt  leaﬂet  tethering  and  decrease  functional  TR
in  normally  right-sided  tricuspid  valves  (B.  Maini,  personal
communication,  January  2015).  However,  there  are  often
wide  malcoaptation  gaps  resulting  from  the  important  tri-
cuspid  annular  dilation  in  severe  secondary  TR,  and  the
MitraClip  System  may  thus  be  a  questionable  solution.
Recently,  initial  experience  with  the  FORMA  repair  sys-
tem  (Edwards  Lifesciences,  Irvine,  CA,  USA)  has  been
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eported  at  congresses  (unpublished  data).  This  new  tech-
ology  is  designed  to  restore  leaﬂet  coaptation  in  patients
ith  functional  TR.  The  device  consists  of  a  spacer  and  a
ail.  The  spacer  is  positioned  into  the  regurgitant  oriﬁce
nd  creates  a  platform  for  leaﬂet  coaptation,  and  the  rail
racks  the  spacer  into  position.  Until  now,  the  device  has
een  implanted  in  seven  patients  with  functional  TR.  The
se  of  this  device  was  associated  with  a  mild-to-moderate
eduction  in  TR,  diuretic  dose  and  peripheral  oedema,  and
n  improvement  in  quality  of  life.  However,  these  results,
lthough  encouraging,  are  preliminary.  The  ongoing  ‘‘Early
easibility  Study  of  the  Edwards  Tricuspid  Transcatheter
epair  System’’  (ClinicalTrials.gov  identiﬁer  NCT02471807)
ill  determine  the  feasibility,  safety  and  efﬁcacy  of  this  new
echnology.
Different  devices  for  the  tricuspid  valve  are  currently
nder  development  in  preclinical  trials.
The  MillipedeTM system  (Millipede,  LLC,  Ann  Arbor,
ichigan,  USA)  involves  the  placement  of  a  tricuspid
nnular  ring  with  an  attachment  system  via  percuta-
eous  methods  to  restore  the  native  tricuspid  annular
hape  and  diameter.  This  device  could  be  repositioned
efore  deployment  and  may  offer  simpler  device  delivery
66].
A  novel  transcatheter  tricuspid  annuloplasty  technique
sing  transatrial  pericardial  access  has  also  been  published
the  TRAIPTA  system)  [67].  This  device  has  been  successfully
mplanted  in  16  swine,  including  four  with  secondary  severe
R.  Under  general  anaethesia  and  mechanical  ventilation,
he  TRAIPTA  system  is  introduced  through  the  femoral  vein
nd  pericardial  access  is  gained  via  puncture  of  the  right
trial  appendage.  The  TRAIPTA  device  is  then  deployed
ircumferentially  in  the  pericardial  space  to  encircle  the
eart  along  the  atrioventricular  groove,  under  the  guid-
nce  of  pericardial  contrast  infusion.  The  contrast  product
s  then  washed  out,  the  right  atrial  appendage  puncture
s  closed  and  the  TRAIPTA  implant  is  then  left  in  place
ermanently.  No  complication  occurred  except  for  moder-
te  pericardial  effusion.  The  dimensions  of  the  tricuspid
nnulus  have  been  signiﬁcantly  reduced  (from  49%  in  the
eptolateral  dimension  and  from  31%  in  the  anteroposterior
iameter).  During  a  follow-up  of  7  to  14  days,  the  TRAIPTA
evice  stayed  in  a  proper  position  and  the  pericardial  effu-
ion  decreased  without  any  drainage.  So,  this  preclinical
tudy  shows  that  TRAIPTA  device  may  be  successfully  pos-
tioned  in  the  atrioventricular  groove  through  a  right  atrial
ppendage  puncture,  and  leads  to  a  signiﬁcant  decrease  in
nnular  dimensions.
These  results  are  encouraging,  but  challenges  remain  to
e  overcome  before  its  use  in  humans,  such  as  the  need
or  a  prophylactic  pericardial  drain  and  the  risk  of  coronary
ompression.
The  ultimate  goal  of  transcatheter  therapy  is  total
ranscatheter  tricuspid  valve  replacement.  However,  the
rst  attempts  with  the  mitral  valve  highlight  the  numer-
us  and  speciﬁc  difﬁculties  encountered  in  atrioventricular
alves  [68].  This  treatment  would  be  applicable  to  patients
ith  previous  left-sided  heart  valve  surgery  who  require
n  extremely  high-risk  redo  isolated  tricuspid  surgery,  but
ight  also  be  feasible  during  transaortic  valve  implantation
r  percutaneous  mitral  valve  implantation,  to  be  in  keeping
ith  surgical  guidelines.
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onclusions
n  recent  years,  the  tricuspid  valve  has  been  recognized  as  a
hallenge  for  new  percutaneous  treatments,  given  the  com-
ination  of  high-risk  dedicated  surgery  and  deterioration
f  surgical  results  over  time.  THV  implantation  is  feasi-
le  in  failed  tricuspid  surgical  valves,  and  may  improve
aemodynamic  and  functional  status.  The  differences  in
eported  approaches  show  that  there  is  no  consensus  for
he  best  strategy  in  these  complex  procedures.  Larger  series
nd  long-term  follow-up  are  needed  to  better  assess  the
ole  of  this  technique  in  the  future.  Moreover,  whereas
esults  for  valve-in-valve  procedures  are  good,  paravalvular
eaks  occurring  with  rigid  annuloplasty  rings  are  a  source  of
oncern.  This  issue  may  improve  in  the  near  future  with  ded-
cated  devices,  which  should  offer  longer  covered  lengths.
For  the  native  tricuspid  valve,  preliminary  results  with
he  two  bicuspidization  techniques  validate  their  feasibility.
ore  experience  is  needed  to  assess  their  clinical  bene-
t  and  deﬁne  the  best  candidates.  Finally,  a  number  of
ther  devices  are  in  preclinical  development,  and  there  is
o  doubt  that  the  next  decade  will  see  the  full  recognition  of
he  tricuspid  valve  in  the  ﬁeld  of  transcatheter  treatments.
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